392 related articles for article (PubMed ID: 15048935)
1. Effects of cyclin-dependent kinase-5 activity on apoptosis and tau phosphorylation in immortalized mouse brain cortical cells.
Shelton SB; Krishnamurthy P; Johnson GV
J Neurosci Res; 2004 Apr; 76(1):110-20. PubMed ID: 15048935
[TBL] [Abstract][Full Text] [Related]
2. A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons.
Zheng YL; Kesavapany S; Gravell M; Hamilton RS; Schubert M; Amin N; Albers W; Grant P; Pant HC
EMBO J; 2005 Jan; 24(1):209-20. PubMed ID: 15592431
[TBL] [Abstract][Full Text] [Related]
3. The levels of cdk5 and p35 proteins and tau phosphorylation are reduced during neuronal apoptosis.
Kerokoski P; Suuronen T; Salminen A; Soininen H; Pirttilä T
Biochem Biophys Res Commun; 2001 Feb; 280(4):998-1002. PubMed ID: 11162625
[TBL] [Abstract][Full Text] [Related]
4. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration.
Patrick GN; Zukerberg L; Nikolic M; de la Monte S; Dikkes P; Tsai LH
Nature; 1999 Dec; 402(6762):615-22. PubMed ID: 10604467
[TBL] [Abstract][Full Text] [Related]
5. p35/Cdk5 pathway mediates soluble amyloid-beta peptide-induced tau phosphorylation in vitro.
Town T; Zolton J; Shaffner R; Schnell B; Crescentini R; Wu Y; Zeng J; DelleDonne A; Obregon D; Tan J; Mullan M
J Neurosci Res; 2002 Aug; 69(3):362-72. PubMed ID: 12125077
[TBL] [Abstract][Full Text] [Related]
6. Mitotic-like tau phosphorylation by p25-Cdk5 kinase complex.
Hamdane M; Sambo AV; Delobel P; Bégard S; Violleau A; Delacourte A; Bertrand P; Benavides J; Buée L
J Biol Chem; 2003 Sep; 278(36):34026-34. PubMed ID: 12826674
[TBL] [Abstract][Full Text] [Related]
7. Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.
Sun LH; Ban T; Liu CD; Chen QX; Wang X; Yan ML; Hu XL; Su XL; Bao YN; Sun LL; Zhao LJ; Pei SC; Jiang XM; Zong DK; Ai J
J Neurochem; 2015 Sep; 134(6):1139-51. PubMed ID: 26118667
[TBL] [Abstract][Full Text] [Related]
8. CDK5-mediated tau accumulation triggers methamphetamine-induced neuronal apoptosis via endoplasmic reticulum-associated degradation pathway.
Xiao N; Zhang F; Zhu B; Liu C; Lin Z; Wang H; Xie WB
Toxicol Lett; 2018 Aug; 292():97-107. PubMed ID: 29705343
[TBL] [Abstract][Full Text] [Related]
9. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles.
Cruz JC; Tseng HC; Goldman JA; Shih H; Tsai LH
Neuron; 2003 Oct; 40(3):471-83. PubMed ID: 14642273
[TBL] [Abstract][Full Text] [Related]
10. A peptide derived from cyclin-dependent kinase activator (p35) specifically inhibits Cdk5 activity and phosphorylation of tau protein in transfected cells.
Zheng YL; Li BS; Amin ND; Albers W; Pant HC
Eur J Biochem; 2002 Sep; 269(18):4427-34. PubMed ID: 12230554
[TBL] [Abstract][Full Text] [Related]
11. Kainate induces AKT, ERK and cdk5/GSK3beta pathway deregulation, phosphorylates tau protein in mouse hippocampus.
Crespo-Biel N; Canudas AM; Camins A; Pallàs M
Neurochem Int; 2007 Jan; 50(2):435-42. PubMed ID: 17116346
[TBL] [Abstract][Full Text] [Related]
12. Cleavage of the cyclin-dependent kinase 5 activator p35 to p25 does not induce tau hyperphosphorylation.
Kerokoski P; Suuronen T; Salminen A; Soininen H; Pirttilä T
Biochem Biophys Res Commun; 2002 Nov; 298(5):693-8. PubMed ID: 12419309
[TBL] [Abstract][Full Text] [Related]
13. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5.
Ahlijanian MK; Barrezueta NX; Williams RD; Jakowski A; Kowsz KP; McCarthy S; Coskran T; Carlo A; Seymour PA; Burkhardt JE; Nelson RB; McNeish JD
Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2910-5. PubMed ID: 10706614
[TBL] [Abstract][Full Text] [Related]
14. Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases beta-amyloid toxicity in cortical neurons.
Li G; Faibushevich A; Turunen BJ; Yoon SO; Georg G; Michaelis ML; Dobrowsky RT
J Neurochem; 2003 Jan; 84(2):347-62. PubMed ID: 12558997
[TBL] [Abstract][Full Text] [Related]
15. Involvement of aberrant cyclin-dependent kinase 5/p25 activity in experimental traumatic brain injury.
Yousuf MA; Tan C; Torres-Altoro MI; Lu FM; Plautz E; Zhang S; Takahashi M; Hernandez A; Kernie SG; Plattner F; Bibb JA
J Neurochem; 2016 Jul; 138(2):317-27. PubMed ID: 26998748
[TBL] [Abstract][Full Text] [Related]
16. Involvement of cyclin dependent kinase5 activator p25 on tau phosphorylation in mouse brain.
Takashima A; Murayama M; Yasutake K; Takahashi H; Yokoyama M; Ishiguro K
Neurosci Lett; 2001 Jun; 306(1-2):37-40. PubMed ID: 11403952
[TBL] [Abstract][Full Text] [Related]
17. Coexpression of human cdk5 and its activator p35 with human protein tau in neurons in brain of triple transgenic mice.
Van den Haute C; Spittaels K; Van Dorpe J; Lasrado R; Vandezande K; Laenen I; Geerts H; Van Leuven F
Neurobiol Dis; 2001 Feb; 8(1):32-44. PubMed ID: 11162238
[TBL] [Abstract][Full Text] [Related]
18. Glutamate treatment and p25 transfection increase Cdk5 mediated tau phosphorylation in SH-SY5Y cells.
Jämsä A; Bäckström A; Gustafsson E; Dehvari N; Hiller G; Cowburn RF; Vasänge M
Biochem Biophys Res Commun; 2006 Jun; 345(1):324-31. PubMed ID: 16678793
[TBL] [Abstract][Full Text] [Related]
19. p35/Cyclin-dependent kinase 5 is required for protection against beta-amyloid-induced cell death but not tau phosphorylation by ceramide.
Seyb KI; Ansar S; Li G; Bean J; Michaelis ML; Dobrowsky RT
J Mol Neurosci; 2007; 31(1):23-35. PubMed ID: 17416967
[TBL] [Abstract][Full Text] [Related]
20. Troglitazone, a thiazolidinedione, decreases tau phosphorylation through the inhibition of cyclin-dependent kinase 5 activity in SH-SY5Y neuroblastoma cells and primary neurons.
Cho DH; Lee EJ; Kwon KJ; Shin CY; Song KH; Park JH; Jo I; Han SH
J Neurochem; 2013 Sep; 126(5):685-95. PubMed ID: 23581463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
